Clinical Trial Update: Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial of CCR5 antagonist GW873140 in treatment-experienced HIV-infected subjects was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• GW873140

Snippet

Sponsor: GlaxoSmithKline | Conditions: HIV Infection | Phase 3 | Status: TERMINATED